Sign in
CompletedNo phase

TIDE Project: Biomarker Discovery for Chronic Tinnitus Diagnosis

Key facts

Who runs it
University of Regensburg
Where
Austin and Champaign, United StatesSee the 2 sitesAlso in 4 other countries, 5 sites
Trial code
Status
Completed
People taking part
560 people enrolled
Started
1 Aug 2024
Ended
30 Nov 2025
Type of study
Observational, 2 groups
Treatments tested
  • Acoustic paradigms
Record updated
24 March 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • (1) for tinnitus cases: a diagnosis of chronic and constant tinnitus (for at least 6 months based on history)
  • (2) for controls: never experienced tinnitus
  • (3) age 18 -70
  • (4) ability to understand and consent to the research
  • (5) ability to participate (hearing ability)
  • (6) MoCa Test ≥ 26
  • (7) hyperacusis questionnaire score < 27

Who cannot take part

  • (8) clinically relevant drug, medication or alcohol abuse up to 12 weeks before study start
  • (9) change in anti-depressants/drugs ≤ 2 weeks
  • (2) otosclerosis; acoustic neuroma or other relevant ear disorders with fluctuating hearing
  • (3) acute ear nose and throat infections (acute otitis media, otitis externa, acute sinusitis)
  • (4) Meniere's disease or similar syndromes
  • (6) serious internal, neurological or psychiatric conditions
  • (7) epilepsy or other CNS disorders (brain tumor, encephalitis)
  • (1) objective tinnitus; heartbeat-synchronous tinnitus as primary complaint
  • (5) vestibular migraine
  • (10) missing written informed consent
  • (11) severe hearing loss - inability to communicate properly in the course of the study
  • (12) one deaf ear

Where in United States

Also in 4 other countries, 5 sites

  • University of TexasAustin, United States
  • University of IllinoisChampaign, United States

About the trial

What the trial wants to find out

Research in clinical neuroscience is founded on the conviction that a better understanding of tinnitus related changes of brain function will improve our ability to diagnose and treat tinnitus. Although considerable advances have been made in understanding the mechanisms of tinnitus, the clinical management of tinnitus remains largely based on a 'trial and error' approach. The identification and validation of a biomarker for tinnitus is thought to be the crucial step in the development of a personalized approach to the diagnosis and treatment of tinnitus. The overarching goal of this study is to incorporate advanced technologies to provide an objective, data-driven, personalized approach to the diagnosis of chronic tinnitus. This should lead to a clinically applicable tool that can be widely and easily used.

The 2 groups in the trial

  • Tinnitus cases/patients

    Subjects that have a diagnosis of chronic and constant tinnitus (for at least 6 months based on history)

    Treatment: Acoustic paradigms

  • Control group

    Subjects that never experienced tinnitus (excluding short-term tinnitus, i.e. not tinnitus that persists over a longer period of time)

    Treatment: Acoustic paradigms

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Identification and Validation of a Biomarker for Tinnitus: an Objective Data-driven Personalized Approach to Diagnosis of Chronic Tinnitus - The Tinnitus Detection (TIDE) Project
Publications
Record updated
24 March 2026